Staphylococcus aureus is one of the most commonly identified pathogens inhuman medicine and is a major cause of nosocomial and community acquiredinfections. Resistance of S. aureus to methicillin was reported for the first time in1961 Methicillin resistance in S. aureus is mediated by the production of an alteredPenicillin-Binding Protein; PBP2a, the production of which is regulated by mec A genecomplex Often, applicable antibiotics for treatment of MRSA are only glycopeptideslike vancomycin and teicoplanin. However, during the last few years, a great problemhas emerged; as some strains of MRSA have displayed intermediate (VISA) or fullresistance (VRSA) to vancomycin. Accordingly, new treatment options for MRSAinfections include daptomycin, linezolid, tigecycline and quinupristin/dalfopristin.Moreover, more recent anti-MRSA drugs are under development; includingdalbavancin, telavancin and oritavancin